UNSPSC 51111725: Acodazole

This classification denotes an intercalating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M28A9O41G. European Medicines Agency schedules Acodazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05245MIG. Acodazole generally arises in the molecular formula C20H19N5O.

UNSPSC 51111725 Acodazole is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though the recent opportunities block shows little activity directly under this specific code. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, with a total contract value of $2,999,999.11 over the initial 12-month term plus two renewal options. Separately, Seminole County, Florida issued an IFB for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building. State and local purchasers under this code appear to include county health departments and state public health agencies accessing cooperative purchasing vehicles and conducting competitive bidding for pharmaceutical inventory.

The geographic spread is limited in the recent record to Illinois and Florida. The Illinois Department of Public Health contract was awarded in August 2026 with a response deadline of September 11, 2026, while the Seminole County IFB was posted on June 30, 2026 with a response deadline of July 26, 2023 (note: the latter deadline appears to be a data error in the source and should not be relied upon for current activity assessment). Neither procurement identified set-aside utilization or domestic product preferences. The code shows sparse recent activity; the two opportunities on record diverge significantly in scope (one covers multiple antibiotic tablets; the other covers opioid-reversal and drug-deactivation products), suggesting either inconsistent code assignment across jurisdictions or that this specific Commodity code does not see substantial activity relative to broader pharmaceutical procurement classifications.